• Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devices
  • Target CRO operates across 20+ countries, providing global clinical development capabilities

WARREN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it is in advanced-stage evaluation of a niche contract research organization (CRO) with multi-country operations and established relationships across oncology, rare diseases, and medical devices.

If completed, the transaction would represent a meaningful step in Tevogen's evolution toward a more diversified, revenue-generating healthcare enterprise. The opportunity is expected to contribute more than $20 million in annual revenue while supporting double-digit growth beginning next year.

The potential combination would bring together two organizations with highly complementary expertise, global reach, and a shared focus on delivering high-quality solutions to clients operating in complex and specialized therapeutic areas. The Company believes this initiative, alongside other strategic evaluations, supports its long-term objective of building a scalable, cash-flow-oriented operating model.